Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GamFluVac Phase 1 Study
NCT03651544Phase 1Completed
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of GamFluVac in Influenza A (IAV) (3 arms). Primary endpoint: Number of Participants With Adverse Events at 28 days. Started Oct 2018; status: completed.
02
Drugs
GamFluVac
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT03651544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651544.